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Abstract
Objective To quantify the effect of opiate substitution treatment in relation
to HIV transmission among people who inject drugs.
Design Systematic review and meta-analysis of prospective published
and unpublished observational studies.
Data sources Search of Medline, Embase, PsychINFO, and the
Cochrane Library from the earliest year to 2011 without language
restriction.
ReviewmethodsWe selected studies that directly assessed the impact
of opiate substitution treatment in relation to incidence of HIV and studies
that assessed incidence of HIV in people who inject drugs and that might
have collected data regarding exposure to opiate substitution treatment
but not have reported it. Authors of these studies were contacted. Data
were extracted by two reviewers and pooled in a meta-analysis with a
random effects model.
Results Twelve published studies that examined the impact of opiate
substitution treatment on HIV transmission met criteria for inclusion, and
unpublished data were obtained from three additional studies. All included
studies examined methadone maintenance treatment. Data from nine
of these studies could be pooled, including 819 incident HIV infections
over 23 608 person years of follow-up. Opiate substitution treatment
was associated with a 54% reduction in risk of HIV infection among
people who inject drugs (rate ratio 0.46, 95% confidence interval 0.32
to 0.67; P<0.001). There was evidence of heterogeneity between studies
(I2=60%, χ2=20.12, P=0.010), which could not be explained by
geographical region, site of recruitment, or the provision of incentives.
There was weak evidence for greater benefit associated with longer
duration of exposure to opiate substitution treatment.
Conclusion Opiate substitution treatment provided as maintenance
therapy is associated with a reduction in the risk of HIV infection among
people who inject drugs. These findings, however, could reflect
comparatively high levels of motivation to change behaviour and reduce
injecting risk behaviour among people who inject drugs who are receiving
opiate substitution treatment.
Introduction
Use of injected drugs is a major risk factor for the acquisition
and transmission of HIV, and about 5-10% of HIV infections
are attributable to injecting drug use worldwide.1 Transmission
of HIV between people who inject drugs is predominantly a
result of the sharing of contaminated injecting equipment, but
also sexual transmission, both of which are influenced by wider
structural and environmental factors such as housing, patterns
of drug use, commercial sex work, and the availability and
nature of interventions aimed at reducing harm.2-4
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Estimates of the prevalence of HIV among people who inject
drugs are over 40% in many parts of the world, and around three
million (range 0.8-6.6 million) of the 16 million (range 11-21
million) people who inject drugs worldwide could be HIV
positive.5 6 Although HIV incidence has fallen or remains low
among people who inject drugs in North America, Australasia,
and parts of Western Europe,3 7-9 injecting drug use has driven
recent outbreaks in Europe,10 as well as epidemics in cities in
the United States, United Kingdom, Thailand, Russia, India,
China, Vietnam, and Estonia,4 11-14 and HIV incidence is
increasing in parts of Russia, Eastern Europe, and Asia, where
the burden of HIV among people who inject drugs is
comparatively higher.5 6 15
Methadone, an opioid agonist, and buprenorphine, a partial
agonist, are the main pharmacological drugs prescribed for
people dependent on opiates, and they were included in the list
of World Health Organization (WHO) essential medicines in
2005. They are provided in oral, film, or sublingual form and
are often prescribed as opiate substitution treatments for people
with established opiate dependence.16 In addition to reducing
craving for, and use of, heroin or other illicit opiates, there is
good evidence to suggest that opiate substitution treatment
reduces drug related mortality, offending, and injection risk
behaviour, and that it improves adherence to antiretroviral
treatment for those with HIV.17-22Methadone and buprenorphine
can also be prescribed in tapering doses for detoxification.
Opiate substitution treatment has been implemented in 70
countries, but remains unavailable in 66, and in several countries
detoxification or residential rehabilitation is the primary mode
of treatment.2 23 Although coverage of opiate substitution
treatment is being expanded in some countries, such as Ukraine,
India, and China,24-26 intervention at a regional and national level
remains poor in many countries, including those with a high
burden of HIV among people who inject drugs.23
Previous reviews have generally concluded that reductions in
the frequency of injection and sharing of injecting equipment
that are associated with exposure to opiate substitution treatment
translate into reductions in cases of HIV infection.21 The
conclusions of these reviews, including a recent Cochrane
systematic review, however, have been based on a small number
of primary studies with limited sample size.19 21 27 Critically, no
pooled analysis has been carried out to date, and as such, there
remains no quantitative estimate of the effect of opiate
substitution treatment in relation to HIV transmission.
We carried out a systematic review and meta-analysis of
published and unpublished observational studies to quantify the
association between opiate substitution treatment and risk of
HIV transmission among people who inject drugs.
Methods
Primary and secondary objectives
Our primary objective was to assess the impact of opiate
substitution treatment in relation to HIV incidence among people
who inject drugs. Secondary research objectives were to examine
the effect of variables including mode of treatment (such as
methadone or buprenorphine; continuous or interrupted
treatment; detoxification treatment); duration of treatment;
geographical region; study setting (such as drug treatment clinic
or other setting); and characteristics of participants (such as age,
sex).
Search strategies
We carried out two separate systematic searches to identify
relevant studies. The first search identified studies that directly
examined the impact of opiate substitution treatment in relation
to HIV incidence. We searched Medline, Embase, and
PsycINFO from the earliest possible year to October 2011 using
the Ovid platform with no limit to language and searched the
Cochrane Library up to 2011. Reference lists of robust literature
reviews were assessed to identify relevant studies. Briefly, terms
included those relating to HIV infection or transmission;
intravenous substance use, misuse, addiction, or dependence;
and substitution, maintenance, methadone or buprenorphine
treatment (table A in appendix 1). The search included exploded
MESH terms and text words to enhance retrieval of relevant
studies.
Secondly, we searched Medline, Embase, and PsycINFO up to
May 2011 to identify prospective cohort studies that reported
HIV incidence in people who inject drugs. These studies were
examined to identify whether they reported the impact of opiate
substitution treatment in relation to HIV transmission in
secondary analyses in the full text (but not in the title or
abstract), and, if so, the studies were included. Authors of studies
of HIV incidence in people who inject drugs that did not report
opiate substitution treatment as a covariate were contacted in
case data regarding exposure to had been collected but not yet
published. The search strategy used similar terms to the first
search but was limited to longitudinal or cohort studies (table
A in appendix 1).
Study selection
After export of all identified studies to Reference Manager 12
and removal of duplicates, two reviewers screened titles and
abstracts and disagreements were resolved by discussion. Two
reviewers screened full text copies of relevant articles to
determine whether they met eligibility criteria for inclusion and
suitability for inclusion in the meta-analysis or for contact of
study authors. Full text papers in languages other than English
were translated by individuals fluent in those languages or, for
one paper, by Google translate.
Data extraction and analysis
Two authors used piloted forms to extract data from studies,
including details of studies (such as year of publication, country,
study design); study characteristics (such as inclusion criteria,
site of recruitment or study); intervention (such as methadone
or buprenorphine maintenance treatment; continuous versus
interrupted treatment; detoxification treatment only); and
intervention effect (seroconversions, follow-up period, incidence
rates, or unadjusted and adjusted measures of effect, including
incidence rate ratio or hazard ratio, and confounders used in
adjusted estimates).
Eligibility criteria
We included studies in this review if they were randomised
controlled trials, prospective cohort studies, or case-control
studies that directly examined the impact of opiate substitution
treatment in relation to HIV incidence in people who inject
drugs; or if they prospectively examined HIV incidence in
people who inject drugs but did not report data regarding the
impact of opiate substitution treatment. We included studies
that assessed the impact of continuous or interrupted opiate
substitution treatment; current, recent, or previous opiate
substitution treatment; or opiate substitution treatment at
baseline. We excluded cross sectional or serial cross sectional
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studies and those studies identifying the outcome from
retrospective analysis of routine medical records to identify
outcome or exposure to opiate substitution treatment (in the
latter case they were considered subject to selection bias because
of different motivations and characteristics of individuals
undergoing voluntary testing). We also excluded studies carried
out in prisons. Studies were included only if data relating to
opiate substitution treatment were reported in opiate injectors.
We excluded studies that reported fewer than two
seroconversions during follow-up to ensure that estimates
generated were sufficiently precise. Participants of the included
studies were people who inject opiates with no restriction around
age, sex, ethnic group, or socioeconomic group. Duplicate papers
from the same cohort study were grouped, and studies with the
largest number of seroconversions or that reported adjusted and
unadjusted analyses, or both, were selected.
Assessment of risk of bias
We assessed risk of bias using recommended criteria28 29 (see
table B in appendix 1). Studies were judged to be at low, high,
or unclear risk of bias on the basis of what was reported in the
study for each of these domains. Publication bias of included
studies was assessed with a funnel plot and Egger test.30 31
Summary measures and synthesis of results
We used Poisson regression to obtain incidence rate ratios and
95% confidence intervals from raw data in unpublished datasets
provided (A Judd, 2012, and S Deren, 2012) and where
information regarding seroconversion and person years of
follow-up was provided in published studies. When only effect
estimates were reported, we directly extracted unadjusted and
adjusted estimates if they were reported as odds ratio, incidence
rate ratio, or hazard ratio with 95% confidence intervals. As the
incidence of HIV in included studies was low (<10/100 person
years), effect estimates that were reported as odds ratios were
extracted directly as it was assumed that the odds ratio was a
reasonable approximate of the relative risk.32
Studies that reported data relating to exposure to opiate
substitution treatment and HIV seroconversion were pooled for
meta-analysis if data were provided regarding HIV
seroconversions, person years of follow-up, and exposure to
opiate substitution treatment; or an effect estimate of the impact
of opiate substitution treatment in relation to HIV incidence
with 95% confidence intervals.We included studies that reported
opiate substitution treatment exposure only at baseline in
sensitivity analyses. We excluded studies that examined
methadone maintenance treatment compared with methadone
detoxification treatment from the primary meta-analysis but
included them in separate subgroup analyses.
As we expected heterogeneity between studies, we used a
random effects meta-analysis for the primary analyses, allowing
for heterogeneity between and within studies. Adjusted and
unadjusted effect estimates were pooled in separate
meta-analyses. We examined heterogeneity with the I2 statistic
and χ2test and explored reasons for heterogeneity using
univariable random effects meta-regression (using the “metareg”
command)33 to compare subgroups by geographical region of
study; the provision of monetary incentives; site of recruitment;
the examined duration of exposure to opiate substitution
treatment; and the percentage of female participants or
individuals from ethnic minorities.
Sensitivity analyses were conducted to include studies that
assessed the impact of exposure to methadone maintenance
treatment at baseline only; the impact of inclusion only of studies
at lower risk of bias (that is, scoring as low risk across three or
fewer domains with the risk of bias tool); including only studies
that measured an incidence rate ratio; and the impact of
excluding those that did not adjust for confounders.
All analyses were carried out with STATA version 11.
Results
Study selection
Figures 1 ⇓ and 2⇓ show the number of studies identified,
reviewed, and selected and the reasons for exclusion. The first
search enabled the identification of seven eligible studies, four
of which included data that could be included in the quantitative
synthesis (fig 1). Three studies were excluded on the basis that
no HIV seroconversions were identified in either treatment
arm.34-36
The second search (fig 2⇓) enabled identification and inclusion
of 10 eligible papers that included data directly relating to the
impact of exposure to opiate substitution treatment in relation
to HIV transmission, of which five were newly identified studies
not identified in the first search.8 11 37-39 In addition, we identified
16 eligible prospective studies that measured HIV incidence
among people who inject drugs and contacted authors of these
articles. Of these, unpublished data were obtained from cohort
studies in London, UK (A Judd, personal communication, 2012);
Montreal, Canada (J Bruneau, personal communication, 2012);
and a dual site study of Puerto Rican injecting drug users in
Bayamon, Puerto Rico, and East Harlem, New York City (S
Deren, personal communication, 2012). Overall, eight studies
were included from this search, seven of which could be
included in the quantitative synthesis (fig 2⇓).
In the second search (fig 2), we excluded one study because no
HIV seroconversions occurred among participants,40 and two
studies that constructed a retrospective cohort based on clinical
records of voluntary testing for hepatitis C virus and HIV.41 42
Seventy one studies were duplicates from the same cohort
(particularly the AmsterdamCohort Study; Vancouver Injection
Drug User Study; and AIDS Linked to Intravenous Experience
(ALIVE) cohort study).
We therefore included 12 published studies8 11 17 37-39 43-48 and the
three unpublished studies, comprising 1016 incident HIV
infections and over 26 738 person years of follow-up.
Study characteristics
Table 1⇓ summarises the characteristics of the 15 included
studies undertaken in the US (including unpublished data from
S Deren, 2012),8 39 43 44 46 Canada (including unpublished data
from J Bruneau, 2012),37 UK (unpublished data from A Judd,
2012), the Netherlands,45 Austria,47 Italy,48 Thailand,11 17 Puerto
Rico (unpublished data from S Deren), and China.38 All of the
included studies reported the impact of methadone maintenance
treatment. The included studies were variable in terms of sample
size (range 80-2546), method of recruitment (drug treatment
clinic (six studies); community settings and outreach (six
studies); drug treatment clinics and community settings (three
studies); duration of follow-up (range 1-20 years), and year of
publication (1992-2009).
Most studies reported the impact of methadone maintenance
treatment as one of a range of factors assessed in relation to the
risk of HIV infection and most reported an associated lower
risk of HIV infection (unpublished data from S Deren and J
Bruneau, 2012).8 38 39 45 47 48 Four studies could not be included
in the meta-analyses because of the comparisons made or the
nature of the data presented (table 1⇓).38 43 47 48 Among these
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studies, Moss and colleagues reported a lower incidence or risk
of HIV among people who inject drugs with more than 12
lifetimemonths of methadonemaintenance treatment compared
with those with less than 12months, and a lower seroconversion
rate among those recruited from methadone maintenance
treatment programmes compared with those recruited from
detoxification programmes or hospital.43 Serpelloni and
colleagues reported a lower risk of seroconversion associated
with methadone dose and cycles of treatment in univariate but
not multivariate analyses.48 Two studies38 47 reported HIV
seroconversions among people who inject drugs out of treatment
but not among those receiving treatment over follow-up (table
1).⇓
All of the included studies were judged to be at high risk of
selection bias and low risk of performance bias and most were
at low risk of ascertainment bias. A few studies, however, were
at high risk of attrition bias (table 2⇓ and table C in appendix
1) and few adjusted for confounders.
Primary meta-analysis
Of the 15 included studies, we were able to pool data from nine
to assess the impact of opiate substitution treatment in relation
to HIV transmission (unpublished data from A Judd and J
Bruneau, 2012),8 17 37 39 44-46 (two additional studies (unpublished
data from SDeren, 2012, and Vanichseni and colleagues11) were
included only in sensitivity or subgroup analyses). The nine
studies predominantly included men (range among studies
61-93%), with median age ranging from 26 to 39, and the
proportion of participants from an ethnic minority group ranging
from 15% to 92%. The sample included 819 incident HIV
infections over 23 608 person years of follow-up.
Random effects meta-analysis showed strong evidence that
opiate substitution treatment was associated with a 54%
reduction in the risk of HIV infection (rate ratio 0.46, 95%
confidence interval 0.32 to 0.67; P<0.001), though there was
heterogeneity between studies (I2=60%, χ2=20.12; P=0.010) (fig
3⇓). Inclusion of unpublished data regarding the impact of
methadone maintenance treatment at baseline (S Deren, 2012)
gave a similar estimate of effect (0.45, 0.32 to 0.65; P<0.001;
test for heterogeneity I2=52.5%, χ2=21.06; P=0.021; fig A in
appendix 2).
Pooling of a subset of six studies that adjusted for confounders
(including unpublished data from SDeren and J Bruneau, 2012)
(see table 1) 17 37 39 44 reduced the sample to 450 incident HIV
infections during over 10 064 person years of follow-up and
suggested that methadonemaintenance treatment was associated
with a 40% reduction in risk of incident HIV infection (rate
ratio 0.60, 0.42 to 0.85; P=0.004; test for heterogeneity I2=23%,
χ2=6.49; P=0.26; fig 3). Furthermore, meta-analysis of a subset
of five studies that excluded those at higher risk of bias
(including unpublished data from J Bruneau, 2012)17 37 49 also
showed effectiveness of opiate substitution treatment (0.61,
0.41 to 0.91; P=0.016 test for heterogeneity: I2=38%, χ2=6.50;
P=0.165); while pooling of a subset of studies for which effect
estimates were expressed only as incidence rate ratio gave a
similar effect (0.53, 0.34 to 0.84; P=0.006; I2=64%, χ2=11.0;
P=0.027; data not shown).
As HIV incidence rates varied substantially between the sites
(from less than one to more than five cases per 100 person
years), we have reported the rate reduction, rather than an
absolute measure of effect (the risk difference), which would
not be generalisable to other sites.
Metaregression analyses
Based on univariable metaregression analyses, we found no
evidence that the effectiveness of opiate substitution treatment
varied according to geographical region or by site of recruitment
(P=0.47 and P=0.59, respectively) (figs 4⇓ and 5⇓; table D in
appendix 1). We also found no evidence to suggest that the
effect of opiate substitution treatment differed by the provision
of incentives to participants (P=0.70; fig B in appendix 2 (top
panel)). Though there was weak evidence that longer duration
of exposure to opiate substitution treatment could be associated
with greater benefit (P=0.18; fig B in appendix 2 (bottom
panel)), the confidence intervals around the summary effect
estimates were wide and few studies assessed exposure over
time periods greater than six months. Lastly, our analyses did
not support a differential impact by the proportion of female
participants or proportion of participants from ethnic minorities
(table D in appendix 1).
Methadone detoxification treatment
Four studies reported the impact of methadone detoxification
treatment, three of which examined detoxification (in the
preceding sixmonths) compared with no treatment (unpublished
data from J Bruneau, 2012)8 17 and one of which examined 45
day methadone detoxification compared with methadone
maintenance treatment in the preceding four months.11 Together
the four studies included 687 incident HIV infections in 20 616
person years of follow-up. HIV incidence was reported to be
higher among those undergoing detoxification treatment (table
3⇓), and our pooled analysis showed no evidence that
detoxification was associated with a decreased risk of HIV
infection compared with either no treatment or methadone
maintenance treatment (relative risk 1.54, 1.05 to 2.26; P=0.026;
n=4 studies; fig 6⇓). The effect was similar when we pooled
studies that compared detoxification with no treatment only
(1.66, 1.04 to 2.66; P=0.035; n=3 studies).
Publication bias
We did not identify studies of small sample size that reported
negative effects of opiate substitution treatment in relation to
HIV transmission in the published literature, although data were
obtained from one small unpublished study. There was weak
evidence of publication bias (Egger’s bias coefficient −1.82;
P=0.052) (fig C in appendix 2).
Discussion
Principal findings
There is evidence from published and unpublished observational
studies that opiate substitution treatment is associated with an
average 54% reduction in the risk of new HIV infection among
people who inject drugs. There is weak evidence to suggest that
greater benefit might be associated with longer measured
duration of exposure to opiate substitution treatment. All of the
eligible studies examined the impact of methadone maintenance
treatment, indicating that there are few data regarding the impact
of buprenorphine or other forms of non-methadone opiate
substitution treatment in relation to HIV transmission.We found
no evidence that methadone detoxification is associated with a
reduction in the risk of HIV transmission.
Strengths and weaknesses of the study
To our knowledge this is the first study that synthesises the
available evidence and generates a quantitative estimate of the
impact of opiate substitution treatment on incidence of HIV. A
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previous Cochrane systematic review concluded that “available
data are limited but it appears that the reductions in risk
behaviour related to drug use do translate into actual reductions
in cases of HIV infection.”21Our review identified an additional
11 studies compared with this review and provided a quantitative
assessment, including data from an additional 924 HIV
seroconversions in over 25 660 additional person years of
follow-up. As such, our study extends and strengthens this
conclusion, providing the most comprehensive quantitative
measure to date of the association between opiate substitution
treatment and risk of incident HIV infection.
This was achieved partly by identifying studies that measured
HIV incidence among people who inject drugs and that reported
the impact of opiate substitution treatment in secondary analyses
(and hence did not report the data in the title or abstract), and
also by identifying studies that might have collected data relating
to opiate substitution treatment but not yet have published the
analyses. Three of 16 authors contacted were able to provide
unpublished data for inclusion in our study, and nine of the 13
other studies were ineligible for inclusion (because opiate
substitution treatment was unavailable when the study was
conducted, data regarding exposure to opiate substitution
treatment were not collected, all participants received treatment,
or the participants were mostly stimulant injectors), while four
authors did not respond (table E in appendix 1). We consider it
unlikely that obtaining additional data from this small number
of additional potential studies would affect our results.
Limitations
Nevertheless, our review has several limitations. All of the
studies included were observational studies subject to bias,
particularly selection and attrition bias. Randomised controlled
trials to assess effectiveness of opiate substitution treatment in
relation to HIV transmission are no longer ethical, however,
given the range of benefits of this treatment,17 19-22 so
meta-analysis of observational analyses, as conducted here, is
required. Nonetheless, the extent to which the studies were
representative of all people who inject drugs and are receiving
opiate substitution treatment is unclear. The proportion of
participants who stopped injecting during opiate substitution
treatment might have varied between cohorts. In addition, it is
possible that cohorts might under-represent short term injectors
and those who have stopped injecting or individuals who have
considerably reduced the frequency of injection during opiate
substitution treatment. For example, such individuals might be
under-sampled in studies of injectors recruited in the community
at needle exchanges or other venues for active injectors,50 and
they might be at decreased risk of HIV infection.11 45 51 If this is
the case, our synthesis would underestimate the reduction in
risk of HIV infection associated with opiate substitution
treatment. Equally, individuals that enter treatment might be
more motivated and more likely to change behaviour, thereby
reducing injecting frequency or the sharing of equipment, or
both, which might overestimate the effect of opiate substitution
treatment on risk of HIV infection.
Our finding regardingmethadone detoxification treatment might
also reflect selection bias if individuals who enter detoxification
are less likely to permanently reduce injecting drug use
compared with those entering opiate substitution treatment. In
some countries, detoxification treatment might be compulsory
or be a requirement before entry to opiate substitution treatment
(as in Thailand, where opiate substitution treatment is provided
only after several unsuccessful attempts at 45 day methadone
detoxification).17 Outcomes of treatment might therefore differ
among those who self initiate treatment with higher motivation
to change compared with those for whom treatment is
compulsory. Additionally, high rates of relapse have been
reported after detoxification,52-54 which might put these
individuals at greater risk of HIV infection. Therefore, if
individuals with less motivation to reduce injecting drug use
and higher relapse rates were more likely to receive methadone
detoxification, the potential impact of detoxification treatment
could be underestimated.
We could not compare the association between type of opiate
substitution treatment and HIV transmission as studies on
non-methadone treatment, such as buprenorphine maintenance
treatment, did not meet eligibility criteria (see table F in
appendix 1). Although this limits generalisability of our findings,
systematic reviews report that several other treatment
outcomes—such as retention—are found to be similar for
buprenorphine and methadone.55 Most studies also used self
reported binary measures of methadone maintenance treatment,
which precluded us from exploring the relation between
methadone dose and risk of HIV infection. Evidence suggests
that doses of at least 60 mg are required with an extended
duration of treatment,45 48 50 and lower doses could be associated
with intermittent injecting during treatment. Despite this
possibility, we found strong evidence of an association between
opiate substitution treatment and reduced risk of HIV
seroconversion, suggesting that the observed associations might
be conservative estimates of the true association between active
engagement with opiate substitution treatment and HIV
transmission.
The control of confounders was limited and inconsistent between
studies, and in those studies that did incorporate confounders
(unpublished data from A Judd and J Bruneau, 2012)17 37 39 the
intervention effect of opiate substitution treatment was diluted,
although still consistent with a strong protective effect. Although
we identified heterogeneity between studies, in meta-regression
analyses, we found no evidence that this was explained by
geographical region, site of recruitment, or the provision of
incentives, although there was weak evidence to suggest that
there could be greater benefit associated with longer recorded
duration of treatment. Published studies provided insufficient
data for exploration of further differences in study design and
reasons for heterogeneity.
We also cannot discount the possibility that part of the impact
of opiate substitution treatment is attributable to the provision
of additional interventions such as attendance at needle and
syringe exchange programmes, psychosocial interventions,
practical support, or supervised injection facilities, which might
additionally reduce the risk of injecting if they are combined
with opiate substitution treatment.19 56 Individual characteristics
such as motivation, social networks, and the extent of
engagement in HIV risk behaviours could also play a role.2
Unfortunately the extent to which additional harm reduction
services were accessed by participants receiving methadone
maintenance treatment could not be deciphered from the data
presented in individual studies; and the use of additional drug
treatment or other support services was included inmultivariable
analyses in only one study, which adjusted for detoxification
treatment.17
Finally, our search strategy targeted opiate substitution
treatment, and our findings on opioid detoxification therefore
need to be treated cautiously as other forms of detoxification
were not included. The risks and benefits of detoxification
should be examined further in future studies, though our findings
are consistent with several studies reporting high rates of HIV
infection among people exposed to detoxification treatment and
in countries where maintenance treatment is unavailable.23 57-61
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Implications
The search strategy we used enabled us to identify several
relevant articles not included in previous narrative or systematic
reviews. In this way, our study suggests that that more
widespread registration of such cohort studies and/or publication
of characteristics of cohort studies and the variables measured62
could play a role in strengthening future systematic reviews
while also limiting publication bias.
Our findings further support and highlight the importance of
opiate substitution treatment in the prevention of HIV among
people who inject (opiate) drugs. The incidence of HIV in people
who inject drugs continues to rise in many parts of the world5 6 15
and HIV infection in such people has been shown to increase
the probability of death almost sixfold (range 3.5-10.1) before
long term cessation of injection, in the absence of antiretroviral
treatment.63 There is good evidence showing that opiate
substitution treatment is associated with reductions in the
frequency of injecting, the sharing of injection equipment, and
drug related HIV risk scores,19 21 and it is likely that the
association between treatment and reduced risk of HIV infection
is mediated by these changes in behaviour. Involvement in such
treatment, as part of a package of interventions, might also
increase engagement with health services and access to care
and services focused on HIV prevention. Opiate substitution
treatment for people who inject drugs and have HIV improves
adherence and the virological response to antiretroviral
treatment, which might therefore reduce the likelihood of
onward transmission.19 64 65
Despite this, the coverage of opiate substitution treatment is
variable worldwide, with recent estimates indicating that only
6-12% of people who inject drugs receive it.23 Critically,
provision of this treatment is minimal in many of the countries
with highest prevalence of HIV in people who inject drugs,66 67
and treatment for opiate dependence with methadone remains
illegal in Russia.58 Increased coverage in many of these
countries,15 24 25 however, is a welcome advance.
Most studies included in our review examined the impact of
opiate substitution treatment alone in relation to HIV
transmission and only one study examined opiate substitution
treatment alone and in combination with needle and syringe
exchange programmes.45 Emerging evidence indicates that
adequate coverage with opiate substitution treatment and needle
and syringe exchange programmes reduces the risk of
transmission of HIV (and hepatitis C virus) to a greater extent
than either intervention alone,45 50 68 and modelling studies
suggest additional benefits in reducing HIV incidence if people
who inject drugs who have HIV receive antiretroviral therapy
(ART) at the same time as opiate substitution treatment and
needle and syringe exchange programmes.69 Further studies are
needed to assess the impact of “comprehensive,” or
combinations of, interventions including opiate substitution
treatment, in a range of settings,19 including prison.70 71Notably,
we identified few studies carried out in low or middle income
countries, and further evidence of the effectiveness of harm
reduction approaches is required in these settings.
Conclusions
HIV/AIDS account for nearly a fifth of the burden of disease
among people who use illicit drugs,72 and increases in HIV
incidence have recently been reported among people who inject
drugs in several different countries across geographical regions.
Our study provides strong quantitative evidence of an association
between opiate substitution treatment and reduced risk of HIV
transmission among people who inject drugs. These data further
support studies showing a range of benefits of opiate substitution
treatment, and support calls for the global increase of harm
reduction interventions to reduce the transmission of HIV
between people who inject drugs and between people who inject
drugs and the wider community.
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Tables
Table 1| Characteristics of included studies of opiate substitution treatment (OST) and impact on HIV transmission
Confounders
included in
Impact of treatment on
HIV seroconversion
Intervention
HIV
incidence
(95% CI)†
Sample
size*Inclusion criteria
Recruitment
site/methodStudy typeFollow-upStudy
adjusted
analyses
Effect
estimate
(95% CI)
Effect
measure
Studies included in meta-analysis
Age, sex,
housing,
cocaine use,
heroin use,
sharing,
booting, having
0.2 (0.0 to
0.7),
adjusted 0.3
(0.1 to 1.3)
HRMMT in
previous 6
months
(yes/no)
2.57 (2.0 to
3.2)
1374Age >18; injected
for past 6 months
Street, word of
mouth,
community
programmes
Cohort1992-2008Bruneau, 2012
(unpublished)‡
Montreal
Canada
sex with person
known to be
HIV positive,
period of
recruitment
Age, sex,
ethnicity
0.3 (0.1 to
0.9),
adjusted 0.7
(0.2 to 2.8)
ORMethadone
treatment in
year before
seroconversion
or last negative
test date
(yes/no)
2.197Cases: participants
testing positive for
HIV infection
1988-1991. Control:
participants testing
negative for HIV
infection within 2
Drug
treatment
programme;
street
Nested
case-control
1988-91Chitwood, 1995,
Miami, US39
week period before
date of first positive
test of case
0.2 (0.0 to
3.5)
IRRMMT at
baseline
(yes/no)
3.7 (2.3 to
6.1)
143Age ≥18, injected
drugs in previous 30
days, use of heroin
in previous 48
hours, self
identification as
Puerto Rican
Targeted
sampling
based on
ethnographic
mapping
Cohort1998-2002Deren, 2012
(unpublished),
Bayamon,
Puerto Rico
0.3 (0.0 to
2.4)
IRRMMT at
baseline
(yes/no)
0.83 (0.3 to
2.2)
154As aboveAs aboveAs aboveDeren, 2012
(unpublished),
New York City,
US
Crack injection,
homelessness
0.8 (0.2 to
3.2),
adjusted 0.8
(0.2 to 3.2)
IRROST for ≥6
months in last
year (yes/no)
2.9272Age <30; injecting
≤6 years; injected
previous 4 weeks;
address for
follow-up
Community,
such as
needle and
syringe
exchange
programmes
Cohort2001-02Judd, 2012
(unpublished),
London, UK
or street
settings
Sex, aboriginal
ethnicity,
frequent
cocaine
injection,
frequent heroin
0.7 (0.4 to
1.1),
adjusted 0.8
(0.5 to 1.4)
RHMethadone
treatment in
previous 6
months
(yes/no)
3.2 (2.6 to
3.7)
1013Injected drugs in
past month; resident
in Vancouver region
Street
outreach; self
referral
Cohort1996-2002Kerr, 2006,
Vancouver,
Canada37
injection,
requiring help
injecting, binge
drug use,
having HIV
positive sexual
partner‡
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Table 1 (continued)
Confounders
included in
adjusted
analyses
Impact of treatment on
HIV seroconversion
Intervention
HIV
incidence
(95% CI)†
Sample
size*Inclusion criteria
Recruitment
site/methodStudy typeFollow-upStudy
Effect
estimate
(95% CI)
Effect
measure
Age, sex,
ethnicity,
needle sharing
0.1 (0.0 to
0.5),
adjusted 0.2
(0.1 to 0.6)
ORMMT over 18
month period
(yes/no)
3.0 in
treatment;
10.7 out of
treatment
185MMT: methadone
programme
participation; no
MMT: >18 years;
Outpatient
methadone
programme;
community
outreach
Cohort1989-91Metzger, 1993,
Philadelphia44
history of
intravenous opiate
use (≥3/week); no
drug treatment in
previous 10 months
0.6 (0.3 to
0.9)
IRRMMT in
previous 6 mo
(yes/no)
3.1 (2.8 to
3.5)
1846Αge ≥18; free from
AIDS at baseline;
injected drugs in
past 10 years
Community
outreach
Cohort1988-98Nelson, 2002,
Baltimore, US8
Incarceration,
injecting drugs,
injecting daily,
sharing
injecting
equipment,
0.8 (0.6 to
1.0),
adjusted 0.60
(0.4 to 0.8)
HRMMT in
previous 6
months
(yes/no)
3.4 (3.0 to
3.9)
2546HIV negative;
history of injected
drug use in previous
year; age 20-60;
informed consent
Drug
treatment
clinics and
community
Nested
cohort in
RCT
1999-2003Suntharasamai,
2009, Bangkok,
Thailand17
participation in
methadone
detoxification
programme§
0.4 (0.2 to
0.5)
IRRAny dose of
MMT daily in
previous 6mo
(yes/no)
1.65710History of ever
injecting drugs;
negative for HIV
and/or HCV
negative at study
entry or at start of
injecting drug use
Drug
treatment
clinics and self
referral
Cohort1985-2005Van den Berg,
2007
Amsterdam,
Netherlands45
0.8 (0.5 to
1.3)
IRRMMT or
detoxification in
previous 4
months
(yes/no)
5.8 (4.8 to
6.8)
1124History of injected
drug use; age
18-50; attendance
at Bangkok
Metropolitan
Administration drug
Drug
treatment
clinic
Cohort1995-98Vanichseni,
2001, Bangkok,
Thailand11
treatment clinics;
not known to be HIV
seropositive
0.2 (0.0 to
1.3)
IRRContinuous
MMT v
interrupted
MMT during
follow-up
2.898History of injected
drug use;
past/current client of
MMT programme;
age ≥18 and one of
three additional
criteria**
Methadone
maintenance
programme
Cohort1992-98Williams, 1992,
New Haven,
US46
Studies not included in meta-analysis
Age, sex,
ethnicity
5.1, adjusted
4.0
HR≤12 lifetime
months in MMT
(yes/no)
1.9681HIV negative
heterosexual people
who inject drugs
tested at least twice
Methadone
maintenance/
detoxification
programmes;
hospital
Cohort1985-90Moss, 1994 San
Francisco, US43
MMT: 0 sc
No MMT:
incidence
2.9/100
person years
—MMT in
previous 6
months
(yes/no)
2.3 (1.1 to
3.5)
229HIV seronegative;
age ≥18; injected of
drugs in previous 3
months; willing to
provide informed
consent
Community
outreach and
peer referral
Cohort2002-05Ruan, 2007,
Xichang City,
China38
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Table 1 (continued)
Confounders
included in
adjusted
analyses
Impact of treatment on
HIV seroconversion
Intervention
HIV
incidence
(95% CI)†
Sample
size*Inclusion criteria
Recruitment
site/methodStudy typeFollow-upStudy
Effect
estimate
(95% CI)
Effect
measure
See
footnote††
—No of cycles of
MMT; daily
—80HIV seronegative
injecting drug users
Drug
dependency
unit
Nested
case-control
1985-91Serpelloni,
1994, Verona,
Italy48 dose; time out
of treatment
(previous 12
months)
MMT: 0/43
sc overmean
1.6 year; No
MMT: 10/59
sc overmean
1.76 years
—MMT for ≥2
months
duration
(yes/no)
5.8102Injecting drug users
attending drug
dependency or
AIDS clinic of
University of
Innsbruck
Drug
dependency
or AIDS clinic
Cohort1985-90Zangerle, 1992,
Innsbruck,
Austria47
(incidence
9.6/100
person
years)
sc=seroconversions; MMT=methadone maintenance treatment; IRR=incidence rate ratio; RH=relative hazard; HR=hazard ratio; OR=odds ratio.
*Size of sample of HIV negative participants in analysis of impact of opiate substitution treatment on HIV incidence.
†As rate per 100 person years. Incidence relates to entire study period when such an estimate was provided in study.
‡Effect estimate adjusted for all variables significantly associated with time to HIV infection in univariate analyses at P≤0.1, as listed. Variables refer to preceding
6 months
§Effect estimate adjusted for all variables significantly associated with incident HIV infection at P≤0.1 in bivariate analysis, as listed.Variables refer to preceding
6 months.
¶Study participants with “no dependence” were excluded from analysis to calculate this estimate from reported data.
**Additional criteria for study entry included: had participated in 1982-83 study of hepatitis and had identifiable serum sample from that study in serum bank of
researchers; had been in methadone programme consistently since 1982; or entered methadone programme between October 1985, and July 1988. Entry into
1982-83 hepatitis study required mild increases in transaminase activity without serological evidence of active hepatitis B infection at time of study (1982-83).
††Lower dose and more time out of treatment associated with increased risk of HIV infection in univariate but not multivariate analyses. Number of cycles of MMT
not significantly associated with risk of HIV infection.
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Table 2| Risk of bias in included studies assessedwith criteria drawn fromNewcastle-Ottawa scale and EPOC group, adapted for assessment
of randomised controlled trials, case-control trials, and prospective observational studies according to criteria recommended by Cochrane
Drugs and Alcohol Review Group28 29
Ascertainment
bias¶
Other bias
Attrition
bias‡
Detection
bias†
Performance
bias*
Selection bias
Study Contamination
Selection of
non-exposed
Comparability
of cohorts§
Allocation
concealment
Random
sequence
generation
LowUnclearUnclearLowHighLowLowHighHighBruneau et al,
unpublished
LowUnclearLowUnclearLowLowLowHighHighChitwood, 199539
LowUnclearLowLowHighLowLowHighHighDeren et al,
unpublished
LowUnclearUnclearLowHighLowLowHighHighJudd et al,
unpublished
LowLowLowLowLowLowLowHighHighKerr, 200637
LowUnclearLowHighLowHighLowHighHighMetzger, 199344
HighHighHighHighHighLowLowHighHighMoss, 199443
LowUnclearLowHighHighLowLowHighHighNelson, 20028
LowUnclearUnclearHighHighLowLowHighHighRuan, 200738
UnclearUnclearLowLowUnclearLowLowHighHighSerpelloni, 199448
LowLowLowLowLowLowLowHighHighSuntharasamai,
200917
LowUnclearLowHighHighLowLowHighHighVan den Berg,
200745
LowUnclearLowHighUnclearLowLowHighHighVanichseni, 200111
UnclearUnclearLowHighHighUnclearLowHighHighWilliams, 199246
LowUnclearLowHighHighLowLowHighHighZangerle, 199247
*Outcome unlikely to be biased by lacking of blinding.
†Objective outcomes, record linkage.
‡Incomplete outcome data.
§Studies deemed at high risk if there was no matching or no adjustment for most important confounding factors.
¶Ascertainment of exposure.
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Table 3| Data regarding HIV incidence and estimate of effect of methadone detoxification treatment in relation to HIV transmission among
people who inject drugs
Rate ratio (95% CI)
HIV incidence per 100 py (95%
CI)
HIV seroconversions/person
yearsExposure variable
1.2 (0.7 to 1.8)6.1 (5.0 to 7.4); 4.9 (3.1 to 7.3)Detox: 106/1730.6; MMT: 24/488.345 day detoxification in past 4 months;
methadone maintenance treatment
Vanichseni et al 200111
1.4 (0.97 to 2.02)Yes: 4.24*; No: 3.03Yes: 33/778; No: 243/8033Detoxification in past 6 months (yes/no)Nelson et al 20028
2.4 (1.8 to 3.3)Yes: 5.3 (4.3-6.6); No: 2.4
(2.0-2.8)
Yes: 89/1666; No: 121/513045-day methadone detoxification in past 6
months (yes/no)
Suntharasamai et al 200917
0.73 (0.18 to 2.99)NANAMethadone detoxification in past 6 months
(yes/no)
Bruneau, 2012
(unpublished)
NA=not available.
*95% confidence intervals were not reported.
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Figures
Fig 1 Selection of studies directly investigating impact of opiate substitution treatment on HIV transmission
Fig 2 Selection of prospective cohort studies relating to HIV incidence in people who inject drugs. Of seven identified, two
were included in sensitivity or subgroup analyses only
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Fig 3 Meta-analysis of studies showing impact of opiate substitution treatment in relation to HIV transmission in people
who inject drugs among all pooled studies and studies reporting only adjusted effect estimates
Fig 4 Impact of opiate substitution treatment in relation to HIV incidence among people who inject drugs by geographical
region
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Fig 5 Impact of opiate substitution treatment in relation to HIV incidence among people who inject drugs by site of recruitment
of study participants
Fig 6 Meta-analysis of included studies showing impact of detoxification treatment on incident HIV infection among people
who inject drugs compared with either no treatment or methadone maintenance treatment
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